- Revive Therapeutics (CSE:RVV) is progressing its Bucillamine treatment in the US and Canada, to combat the COVID-19 pandemic
- The company is currently putting together its Investigational New Drug package for the US Food and Drug Administration, which it expects to submit in June
- Revive is also developing a similar package for Health Canada and expects to receive feedback in June.
- Alongside this news, the company has expanded its drug delivery licensing agreement with Wisconsin Alumni Research Foundation to also include other hallucinogenic compounds
- Revive Therapeutics (RVV) is up 14.29 per cent, with shares trading for C$0.16 and a market cap of $9.73 million
Revive Therapeutics (CSE:RVV) is progressing its COVID-19 drug candidate in the US and Canada, while also developing its recent foray into psychedelics.
The company has recently been developing its Bucillamine treatment to combat the COVID-19 pandemic.
Revive is currently putting together its Investigational New Drug package for the US Food and Drug Administration.
The FDA has recommended the company jump straight into a confirmatory clinical trial.
Toward this end, Revive is now developing its package with a clinical trial in mind and is also developing a similar package for Health Canada, to make the progress the treatment there as well.
By June, the company expects to have submitted its FDA package and received feedback from Health Canada, regards its Canadian new drug application. Once approvals are given, the company hopes to begin trailing Bucillamine as a treatment for COVID-19 as soon as possible.
Outside of the pandemic, the company has also been developing its partnership in the emerging psychedelics market.
The company recently began a research partnership with University of Wisconsin-Madison to progress psilocybin-based pharmaceuticals. Since then, the company has expanded its drug delivery licensing agreement with Wisconsin Alumni Research Foundation to also include other hallucinogenic compounds.
Through the agreement, the company hopes to develop psilocybin-based topical gels, creams or ointments, oral or transdermal patches, oral dosages and foams.
Michael Frank, Revive’s CEO, commented on the company’s recent progress.
“We are advancing our main programs in COVID-19 and psychedelics with the aim to initiate clinical studies in the short-term while leveraging our assets and building our pharmaceutical-based product pipeline for long-term growth,” he said.
Revive Therapeutics (RVV) is up 14.29 per cent, with shares trading for C$0.16 at 11:55am EDT.
